Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 16, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, comment on the need for more inclusive clinical trial patient enrollment criteria, highlighting underserved patient populations in episode 2 of the NeurologyLive® Peer Exchange series, "Multiple Sclerosis Treatments on the Horizon: BTK Inhibitors."
Following along with NeurologyLive®'s coverage of the International Parkinson and Movement Disorder Society (MDS) Annual Meeting, which gathers thousands of clinicians, researchers, trainees, and industry supporters to discuss the diagnosis and treatment of movement disorders on an annual basis.
In the latest edition of our in-depth Q&A series, the molecular biologist at the Cleveland Clinic Lerner Research Institute discussed the unanswered questions regarding biomarkers sTREM2 and GFAP, and the role they play in Alzheimer pathology.
Treatment with NurOwn resulted in response on several secondary outcomes, including timed 25-foot walk, 12-item multiple sclerosis walking scale, and low contrast letter acuity, among others.
The professor of pediatrics at Case Western University discussed the complexities and negative effects for children drastically change their sleep schedules as school begins.